ETFs

ETF (UCITS compliant)

L&G Pharma Breakthrough UCITS ETF

USD Accumulating ETF Class

ISINIE00BF0H7608

TER0.49%

Fund aim

The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").

Fund snapshot

  • Long-term allocation

Long-term value in a pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives

  • High growth potential

Aims to capture the future growth opportunity in orphan drugs

  • Leveraging industry expertise

An index tracking investment strategy that is supported by a team of pharmaceutical experts

  • Does it have a sustainable objective?

The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.

Fund facts

Fund size
Base currency USD
Fund launch date 15 Dec 2017
Share class launch 23 Jan 2018
Domicile Ireland
Replication method Physical - full replication

Benchmark

Solactive Pharma Breakthrough Value Index

Index description

Solactive Pharma Breakthrough Value Index Net TR USD

The Index is comprised of bio-technology companies which are publicly traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently “liquid” (a measure of how actively its shares are traded on a daily basis).

The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.

Index data

ProviderSolactive
Bloomberg codeSOLBIOT
Reuters code.SOLBIOT
TypeNet Total Return
WebsiteGo to website

Performance

Performance for the USD Accumulating unit class in USD, launched on 23 January 2018. Source: Lipper. Performance assumes all ETF charges have been taken and that all income generated by the investments, after deduction of tax, remains in the ETF.
Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past. The tables and charts above shows the fund's performance as the percentage loss or gain per year over the last 10 years.
Share class launch date: 23 Jan 2018
Benchmark: Solactive Pharma Breakthrough Value Index Net TR USD
Share class launch date: 23 Jan 2018
Benchmark: Solactive Pharma Breakthrough Value Index Net TR USD

Performance scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.
What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.
The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product with input from the over the last 10 years. Markets could develop very differently in the future.

Example investment: 10,000 USD

Data for the selected period isn't currently available

Portfolio breakdown

Top 10 constituents27.0%
Rest of Index73.0%
Number of constituents in Index41

Top 10 constituents (%)

Xeris Biopharma2.9
United Therapeutics2.9
Ligand Pharmaceuticals2.8
Basilea Pharmaceutica Ltd2.7
Genmab A/S2.7
Eisai2.6
Biogen Inc2.6
Beone Medicines2.6
AstraZeneca2.6
Agios Pharmaceuticals2.6

Sector (%)

Health Care
97.7
Materials
2.3

All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding. The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.

Loading recommendations…

Fund managers

L&G Index Fund Management Team headshot

L&G Index Fund Management Team

The skill set and expertise we have developed over 35+ years in index management has allowed us to continuously evolve our investment processes. The Index Fund Management team comprises 30 fund managers with an average experience of 15 years, supported by 33 broader team members. Management oversight is provided by Dave Barron, Global Head of Index, ETFs & Systematic Solutions. The team also has full access to the resources and research of other specialists within L&G, including economists and strategists.

SFDR categorisation

The sustainable investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund and seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.

Literature

Prices

Pricing information

Price time16:00 EST (NY)
CurrencyUSD
Monthly price history

Download full price history

Listings and codes

Listings

ExchangeCurrencyTickerISINBloombergWKNReutersListing dateTrading hours (local)
London Stock Exchange
GBPBIGTIE00BF0H7608BIGT LNA2H9XRBIGT.L23/01/201808:00 - 16:30
London Stock Exchange
USDBIOTIE00BF0H7608BIOT LNA2H9XRGEBIOT.L23/01/201808:00 - 16:30
Borsa Italiana
EURBIOTIE00BF0H7608BIOT IMA2H9XRECBIOT.MI23/02/201809:00 - 17:30
Deutsche Börse Xetra
EURETLIIE00BF0H7608ETLI GYA2H9XRETLI.DE06/02/201809:00 - 17:30
Euronext Amsterdam
EURBIOTIE00BF0H7608BIOT NAA2H9XRGOBIOT.AS01/02/201809:00 - 17:30
SIX Swiss Exchange
CHFBIOTIE00BF0H7608BIOT SWA2H9XRBIOTC.S05/06/202009:00 - 17:30

Share class codes

ISINIE00BF0H7608
SEDOLBF0H760
BloombergBIOT
WKNA2H9XR

Dealing information

IssuerLegal & General UCITS ETF Plc
Depositary and TrusteeThe Bank of New York Mellon SA/NV, Dublin Branch
Securities regulatorCentral Bank of Ireland

Country registration

This share class is registered for sale in the following countries:

Austria
Denmark
Finland
France
Germany
Ireland
Italy
Luxembourg
Netherlands
Norway
Spain
Sweden
Switzerland
United Kingdom